Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains

ACS Chemical Biology

Volumn 8, Issue 11, 2013, Pages 2360-2365

  Martin, Mathew P ^a   Olesen, Sanne H ^a   Georg, Gunda I ^b   Schönbrunn, Ernst ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL LYSINE; CYCLIN DEPENDENT KINASE 2; DINACICLIB; LYSINE; UNCLASSIFIED DRUG; BRD1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; NUCLEAR PROTEIN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIDINIUM DERIVATIVE;

ARTICLE; BACTERIAL CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG PROTEIN BINDING; HYDROGEN BOND; MOLECULAR RECOGNITION; NONHUMAN; PHARMACOPHORE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; LYSINE; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIDINIUM COMPOUNDS;

EID: 84887940786     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4003283     Document Type: Article

References (31)

1. Owen, D. J., Ornaghi, P., Yang, J. C., Lowe, N., Evans, P. R., Ballario, P., Neuhaus, D., Filetici, P., and Travers, A. A. (2000) The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p EMBO J. 19, 6141-6149
2. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J. P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Muller, S., Pawson, T., Gingras, A. C., Arrowsmith, C. H., and Knapp, S. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family Cell 149, 214-231
3. Filippakopoulos, P. and Knapp, S. (2012) The bromodomain interaction module FEBS Lett. 586, 2692-2704
4. Denis, G. V. (2010) Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation Discovery Med. 10, 489-499
5. Chung, C. W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. A., Boursier, E. V., Flynn, H., Bouillot, A. M., Bamborough, P., Brusq, J. M., Gellibert, F. J., Jones, E. J., Riou, A. M., Homes, P., Martin, S. L., Uings, I. J., Toum, J., Clement, C. A., Boullay, A. B., Grimley, R. L., Blandel, F. M., Prinjha, R. K., Lee, K., Kirilovsky, J., and Nicodeme, E. (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains J. Med. Chem. 54, 3827-3838
6. Hewings, D. S., Rooney, T. P., Jennings, L. E., Hay, D. A., Schofield, C. J., Brennan, P. E., Knapp, S., and Conway, S. J. (2012) Progress in the development and application of small molecule inhibitors of bromodomain-acetyl- lysine interactions J. Med. Chem. 55, 9393-9413
7. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains Nature 468, 1067-1073
8. Bamborough, P., Diallo, H., Goodacre, J. D., Gordon, L., Lewis, A., Seal, J. T., Wilson, D. M., Woodrow, M. D., and Chung, C. W. (2012) Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides J. Med. Chem. 55, 587-596
9. Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., McCleary, S., Rioja, I., Bamborough, P., Chung, C. W., Gordon, L., Lewis, T., Walker, A. L., Cutler, L., Lugo, D., Wilson, D. M., Witherington, J., Lee, K., and Prinjha, R. K. (2012) Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 22, 2968-2972
10. Zhao, L., Cao, D., Chen, T., Wang, Y., Miao, Z. H., Xu, Y., Chen, W., Wang, X., Li, Y., Du, Z., Xiong, B., Li, J., Xu, C., Zhang, N., He, J., and Shen, J. (2013) Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain J. Med. Chem. 56, 3833-3851
11. LaRonde-LeBlanc, N. and Wlodawer, A. (2005) The RIO kinases: an atypical protein kinase family required for ribosome biogenesis and cell cycle progression Biochim. Biophys. Acta 1754, 14-24
12. Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., III, and Singer, D. S. (2012) BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain Proc. Natl. Acad. Sci. U.S.A. 109, 6927-6932
13. Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., Nomeir, A., Windsor, W., Fischmann, T., Wang, Y., Oft, M., Chen, T., Kirschmeier, P., and Lees, E. M. (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor Mol. Cancer Ther. 9, 2344-2353
14. Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C., Chan, T.-Y., Doll, R. J., Keertikar, K., Knutson, C., McKittrick, B., Rivera, J., Rossman, R., Tucker, G., Fischmann, T., Hruza, A., Madison, V., Nomeir, A. A., Wang, Y., Kirschmeier, P., Lees, E., Parry, D., Sgambellone, N., Seghezzi, W., Schultz, L., Shanahan, F., Wiswell, D., Xu, X., Zhou, Q., James, R. A., Paradkar, V. M., Park, H., Rokosz, L. R., Stauffer, T. M., and Guzi, T. J. (2010) Discovery of dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases ACS Med. Chem. Lett. 1, 204-208
15. Guha, M. (2012) Cyclin-dependent kinase inhibitors move into Phase III Nat. Rev. Drug Discovery 11, 892-894
16. Johnson, L. N. (2009) Protein kinase inhibitors: contributions from structure to clinical compounds Q. Rev. Biophys. 42, 1-40
17. Sherr, C. J. (1996) Cancer cell cycles Science 274, 1672-1777
18. Weinberg, R. A. (1995) The retinoblastoma protein and cell cycle control Cell 81, 323-330
19. van den Heuvel, S. and Harlow, E. (1993) Distinct roles for cyclin-dependent kinases in cell cycle control Science 262, 2050-2054
20. Cicenas, J. and Valius, M. (2011) The CDK inhibitors in cancer research and therapy J. Cancer Res. Clin. Oncol. 137, 1409-1418
21. Massard, C., Soria, J. C., Anthoney, D. A., Proctor, A., Scaburri, A., Pacciarini, M. A., Laffranchi, B., Pellizzoni, C., Kroemer, G., Armand, J. P., Balheda, R., and Twelves, C. J. (2011) A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors Cell Cycle 10, 963-970
22. Schonbrunn, E., Betzi, S., Alam, R., Martin, M. P., Becker, A., Han, H., Francis, R., Chakrasali, R., Jakkaraj, S. R., Kazi, A., Sebti, S. M., Cubitt, C. L., Gebhard, A. W., Hazlehurst, L., Tash, J. S., and Georg, G. I. (2013) Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases J. Med. Chem. 56, 3768-3782
23. Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., Knapp, S., and Bradner, J. E. (2012) Small-molecule inhibition of BRDT for male contraception Cell 150, 673-684
24. Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., Robson, S. C., Chung, C. W., Hopf, C., Savitski, M. M., Huthmacher, C., Gudgin, E., Lugo, D., Beinke, S., Chapman, T. D., Roberts, E. J., Soden, P. E., Auger, K. R., Mirguet, O., Doehner, K., Delwel, R., Burnett, A. K., Jeffrey, P., Drewes, G., Lee, K., Huntly, B. J., and Kouzarides, T. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 478, 529-533
25. Norman, M. H., Liu, L., Lee, M., Xi, N., Fellows, I., D'Angelo, N. D., Dominguez, C., Rex, K., Bellon, S. F., Kim, T. S., and Dussault, I. (2012) Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives J. Med. Chem. 55, 1858-1867
26. Betzi, S., Alam, R., Martin, M., Lubbers, D. J., Han, H., Jakkaraj, S. R., Georg, G. I., and Schonbrunn, E. (2011) Discovery of a potential allosteric ligand binding site in CDK2 ACS Chem. Biol. 6, 492-501
27. Kabsch, W. (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Crystallogr. 26, 795-800
28. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 213-221
29. Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics AActa Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132
30. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current developments Acta Crystallogr., Sect. D: Biol. Crystallogr. 67, 235-242
31. Collaborative Computational Project, Number 4. (1994) The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 50, 760-763